Cargando…
518. Characterization of colistin-resistant (COL-R) Acinetobacter baumannii calcoaceticus complex (ABC) isolates from a recent, global Phase 3 trial (ATTACK)
BACKGROUND: Due to the lack of effective therapies, last-resort agents such as colistin are more frequently being used to treat drug-resistant ABC infections. Consequently, COL-R ABC is becoming more common, with some countries such as Greece reporting rates of >50%(1). The efficacy and safety of...
Autores principales: | Moussa, Samir, McLeod, Sarah, Miller, Alita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752379/ http://dx.doi.org/10.1093/ofid/ofac492.573 |
Ejemplares similares
-
1254. In vitro activity of sulbactam-durlobactam against recent global clinical Acinetobacter baumannii-calcoaceticus complex isolates
por: McLeod, Sarah, et al.
Publicado: (2020) -
85. Efficacy of Sulbactam-Durlobactam (SUL-DUR) Compared to Colistin (COL) against Acinetobacter baumannii-calcoaceticus Complex (ABC) Monomicrobial and Polymicrobial Infections in a Phase 3 Trial
por: Miller, Alita, et al.
Publicado: (2023) -
In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021
por: Karlowsky, James A., et al.
Publicado: (2022) -
1293. Sulbactam-durlobactam is active against recent, multi-drug resistant Acinetobacter baumannii clinical isolates from the Middle East
por: Miller, Alita, et al.
Publicado: (2020) -
Risk factors and clinical responses of pneumonia patients with colistin-resistant Acinetobacter baumannii-calcoaceticus
por: Aydemir, Hande, et al.
Publicado: (2019)